Dr. Robert D. Schreiber is the director of the Center for Human Immunology and Immunotherapy Programs, and a professor in the Department of Molecular Microbiology at Washington University School of Medicine.
Dr. Schreiber has been a pivotal figure in validating and advancing the theory of cancer immunosurveillance and immunoediting, the processes by which our immune systems monitor, control, and shape the development of cancer. Among his honors, Dr. Schreiber has received the 2001 William B. Coley Award for Distinguished Research in Basic and Tumor Immunology, the 2014 AACR-CRI Lloyd J. Old Award in Cancer Immunology, and the 2017 Balzan Prize. He has also been elected to the National Academy of Sciences and the American Association for the Advancement of Science. His current work continues to characterize how various immune signaling pathways, as well as tumor mutations, influence anti-tumor immune responses.
In addition to his role as an associate director of CRI’s Scientific Advisory Council, Dr. Schreiber is the chairman of the CLIP Grant Review Committee and serves on the Postdoctoral Fellowship Review Committee. He is also the editor-in-chief of the CRI/AACR journal Cancer Immunology Research, and is a lead investigator in CRI’s partnership with the Parker Institute for Cancer Immunotherapy, which seeks to develop neoantigen-based personalized cancer vaccines.
Learn more about Dr. Schreiber’s incredible career
We believe we can incorporate [mutated tumor] proteins into vaccines that only unleash the T cells on the tumors, and so far, our tests have been very successful.
¡Hagamos correr la voz sobre la inmunoterapia! Haga clic para compartir esta página con su comunidad.